Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors

Detalhes bibliográficos
Autor(a) principal: Oliveira,Renata B de
Data de Publicação: 2006
Outros Autores: Vaz,Aline BM, Alves,Rosana O, Liarte,Daniel B, Donnici,Claudio L, Romanha,Alvaro J, Zani,Carlos L
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Memórias do Instituto Oswaldo Cruz
Texto Completo: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762006000200009
Resumo: The natural lignans veraguensin and grandisin have been reported to be active against Trypanosoma cruzi bloodstream forms. Aiming at the total synthesis of these and related compounds, we prepared three 2-arylfurans and eight 2,5-diarylfurans. They were evaluated for their potential as T. cruzi trypanothione reductase (TR) inhibitors as well against the parasite's intracellular (amastigote) and bloodstream (trypomastigote) forms. Compound 12 was the most effective against TR with an IC50 of 48.5 µM while 7 and 14 were active against amastigotes, inhibiting the parasite development by 60% at 20 µg/ml (59 and 90 µM, respectively). On the other hand, none of the compounds was significantly active against the parasite bloodstream forms even at 250 µg/ml (0.6-1.5 mM).
id FIOCRUZ-4_67bdf1ef7dca952ae9b2f7c184fdf3e8
oai_identifier_str oai:scielo:S0074-02762006000200009
network_acronym_str FIOCRUZ-4
network_name_str Memórias do Instituto Oswaldo Cruz
spelling Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitorstropical diseasesChagas diseasearylfuranstrypanothione reductaseThe natural lignans veraguensin and grandisin have been reported to be active against Trypanosoma cruzi bloodstream forms. Aiming at the total synthesis of these and related compounds, we prepared three 2-arylfurans and eight 2,5-diarylfurans. They were evaluated for their potential as T. cruzi trypanothione reductase (TR) inhibitors as well against the parasite's intracellular (amastigote) and bloodstream (trypomastigote) forms. Compound 12 was the most effective against TR with an IC50 of 48.5 µM while 7 and 14 were active against amastigotes, inhibiting the parasite development by 60% at 20 µg/ml (59 and 90 µM, respectively). On the other hand, none of the compounds was significantly active against the parasite bloodstream forms even at 250 µg/ml (0.6-1.5 mM).Instituto Oswaldo Cruz, Ministério da Saúde2006-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762006000200009Memórias do Instituto Oswaldo Cruz v.101 n.2 2006reponame:Memórias do Instituto Oswaldo Cruzinstname:Fundação Oswaldo Cruzinstacron:FIOCRUZ10.1590/S0074-02762006000200009info:eu-repo/semantics/openAccessOliveira,Renata B deVaz,Aline BMAlves,Rosana OLiarte,Daniel BDonnici,Claudio LRomanha,Alvaro JZani,Carlos Leng2020-04-25T17:49:33Zhttp://www.scielo.br/oai/scielo-oai.php0074-02761678-8060opendoar:null2020-04-26 02:13:42.359Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruztrue
dc.title.none.fl_str_mv Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors
title Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors
spellingShingle Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors
Oliveira,Renata B de
tropical diseases
Chagas disease
arylfurans
trypanothione reductase
title_short Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors
title_full Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors
title_fullStr Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors
title_full_unstemmed Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors
title_sort Arylfurans as potential Trypanosoma cruzi trypanothione reductase inhibitors
author Oliveira,Renata B de
author_facet Oliveira,Renata B de
Vaz,Aline BM
Alves,Rosana O
Liarte,Daniel B
Donnici,Claudio L
Romanha,Alvaro J
Zani,Carlos L
author_role author
author2 Vaz,Aline BM
Alves,Rosana O
Liarte,Daniel B
Donnici,Claudio L
Romanha,Alvaro J
Zani,Carlos L
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Oliveira,Renata B de
Vaz,Aline BM
Alves,Rosana O
Liarte,Daniel B
Donnici,Claudio L
Romanha,Alvaro J
Zani,Carlos L
dc.subject.por.fl_str_mv tropical diseases
Chagas disease
arylfurans
trypanothione reductase
topic tropical diseases
Chagas disease
arylfurans
trypanothione reductase
dc.description.none.fl_txt_mv The natural lignans veraguensin and grandisin have been reported to be active against Trypanosoma cruzi bloodstream forms. Aiming at the total synthesis of these and related compounds, we prepared three 2-arylfurans and eight 2,5-diarylfurans. They were evaluated for their potential as T. cruzi trypanothione reductase (TR) inhibitors as well against the parasite's intracellular (amastigote) and bloodstream (trypomastigote) forms. Compound 12 was the most effective against TR with an IC50 of 48.5 µM while 7 and 14 were active against amastigotes, inhibiting the parasite development by 60% at 20 µg/ml (59 and 90 µM, respectively). On the other hand, none of the compounds was significantly active against the parasite bloodstream forms even at 250 µg/ml (0.6-1.5 mM).
description The natural lignans veraguensin and grandisin have been reported to be active against Trypanosoma cruzi bloodstream forms. Aiming at the total synthesis of these and related compounds, we prepared three 2-arylfurans and eight 2,5-diarylfurans. They were evaluated for their potential as T. cruzi trypanothione reductase (TR) inhibitors as well against the parasite's intracellular (amastigote) and bloodstream (trypomastigote) forms. Compound 12 was the most effective against TR with an IC50 of 48.5 µM while 7 and 14 were active against amastigotes, inhibiting the parasite development by 60% at 20 µg/ml (59 and 90 µM, respectively). On the other hand, none of the compounds was significantly active against the parasite bloodstream forms even at 250 µg/ml (0.6-1.5 mM).
publishDate 2006
dc.date.none.fl_str_mv 2006-03-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762006000200009
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762006000200009
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0074-02762006000200009
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Oswaldo Cruz, Ministério da Saúde
publisher.none.fl_str_mv Instituto Oswaldo Cruz, Ministério da Saúde
dc.source.none.fl_str_mv Memórias do Instituto Oswaldo Cruz v.101 n.2 2006
reponame:Memórias do Instituto Oswaldo Cruz
instname:Fundação Oswaldo Cruz
instacron:FIOCRUZ
reponame_str Memórias do Instituto Oswaldo Cruz
collection Memórias do Instituto Oswaldo Cruz
instname_str Fundação Oswaldo Cruz
instacron_str FIOCRUZ
institution FIOCRUZ
repository.name.fl_str_mv Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruz
repository.mail.fl_str_mv
_version_ 1669937695812485120